DGAP-News: STADA receives approval for Erythropoietin-zeta – market launch in Q1/2008

| Source: EQS Group AG EQS Group AG 

STADA Arzneimittel AG / Regulatory Approval

19.12.2007 

Release of a Corporate-announcement, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Today, on December 19, 2007, STADA received, as expected, in the scope of
an EU-wide approval process for Erythropoietin-zeta (Epo-zeta), the
approval for the treatment of anaemia associated with chronic renal failure
and chemotherapy from the EU Commission.

Thus, in the scope of a sales license granted by BIOCEUTICALS Arzneimittel
AG, STADA will be able to market Epo-zeta in Germany under the brand name
Silapo® in the first quarter of 2008 via the Group-owned sales company cell
pharm GmbH. Due to further license agreements, Hospira, Inc., a U.S.-based
global specialty pharmaceutical and medication delivery company, as is
known, will be able to market Epo-zeta in the EU under the brand name
Retacrit™ from the first quarter of 2008.

For further details see STADA Corporate News from October 19, 2007 and
November 20, 2006.


Further information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 
61118 Bad Vilbel, Germany / Phone: +49(0) 6101 603-113 /
Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de
Or visit our website at www.stada.com
DGAP 19.12.2007 
---------------------------------------------------------------------------
Language:     English
Issuer:       STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Deutschland
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
              Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------